The MFN Paradox: Protecting Global Asset Value in a Referenced World

The MFN Paradox is not about pricing. It is about controlling global value in a fully interconnected system.

Executive Summary

MFN is not just a pricing policy.

It is a structural reset of how pharmaceutical value is created, protected, and transferred across markets.

Most organizations are still reacting at the level of list price.

The real exposure sits elsewhere:in the gross-to-net architecture, launch sequencing logic, and cross-country referencing loops.

This is where value will be lost. Or protected.

Stratence Partners, in collaboration with Andersen, addresses this challenge at its root:turning MFN from a margin risk into a controlled commercial system.

1. MFN Is Not a Regulation. It Is a System Shock

MFN introduces a simple rule with complex consequences:

The US price for CMS becomes anchored to the lowest list price or, probably more favorable, the volume-adjusted average net price across reference markets.

But the impact is not linear. It is systemic.

A decision in one country propagates across:

• Pricing corridors

• Market access agreements

• Rebates and discounts

• Portfolio-level profitability

What was previously a local pricing decision becomes a global asset valuation trigger.

Most organizations are not built for this.

They operate with:

• Fragmented pricing logic

• Limited net price visibility

• Disconnected Market Access and Commercial decisions

Under MFN, this is not inefficient.

It is dangerous.

2. The End of Traditional Launch Strategy

The classic launch sequence is broken.

Historically:

• Launch early in high-price markets

• Expand progressively

• Optimize locally

Under MFN:

• Early low-price exposure can irreversibly anchor global price ceilings 

• Market entry decisions become valuation decisions 

• Timing becomes as critical as price itself

This is not a sequencing problem anymore.

It is a simulation problem.

Leading organizations are shifting from:

“Where do we launch?”

to

“What is the global price impact of any launch scenario?”

This requires:

• Cross-country reference modeling

• GDP-adjusted benchmarking logic (as emerging under Method II)

• Portfolio-level price exposure simulations

Without this, MFN decisions are blind.

3. The Real Battlefield: Gross-to-Net Control

MFN will not be managed at list price level only.

It will be managed also at net price level.

Aleksandar Ruzicic, Senior VP Healthcare at Stratence, frames it clearly:

The shift towards volume-weighted net price referencing (Method II) means that every rebate, discount and contractual condition becomes globally relevant.

This changes everything.

Organizations now need to control:

• Discounts

• Rebates

• Access agreements

• Tender structures

• Cost-to-serve logic

Across multiple countries simultaneously.

This is not a pricing exercise.

It is a full gross-to-net governance challenge.

As demonstrated in recent global pharma transformations led by Stratence:

In a large multinational environment, limited net price visibility and inconsistent discounting structures were creating structural margin leakage across markets.

By implementing a fully integrated Single Point of Truth (SPOT™) and restructuring the gross-to-net waterfall, we enabled transaction-level transparency and consistent decision-making across products, customers, and geographies.

The result was not only multi-million EBIT improvement, but more importantly, the ability to actively control pricing outcomes rather than react to them.

Under MFN, this is no longer optional.

This is the minimum requirement to protect asset value.

4. From Pricing Decisions to Decision Systems

The core issue is not pricing capability.

It is decision architecture.

Most pharma organizations:

• Analyze data

• Generate insights

• Run pilots

But fail to embed decisions into:

• Governance

• Commercial cadence

• Execution logic

As highlighted in Stratence’s transformation model:

AI creates value only when it is embedded into strategy, access, pricing, and execution decisions 

MFN amplifies this gap.

To operate effectively, organizations need:

• Scenario-based decision frameworks

• Defined pricing corridors

• Exception governance mechanisms

• Cross-functional alignment (Finance, Market Access, Commercial)

Gross-to-net must evolve from:

Reporting

to

Controlled decision system 

5. The Stratence Approach: Controlling the MFN Exposure

Stratence does not optimize pricing.

It redesigns the full commercial system.

The approach is structured around three capabilities:

1. Full Transparency (SPOT™)

• Integrated data environment

• Transaction-level profitability

• Cross-country visibility

2. Predictive Intelligence (SPIE+AI™)

• Scenario simulation (launch, access, pricing)

• Net price exposure modeling

• Reference price propagation analysis

3. Execution Discipline (Governance & Corridors)

• Pricing corridors and thresholds

• Deal-level decision rules

• Embedded governance across functions

This enables organizations to:

• Anticipate MFN impact before it materializes

• Optimize pricing structures proactively

• Protect global asset value across markets

6. Andersen + Stratence: From Compliance to Competitive Advantage

MFN is not only a commercial challenge.

It is also:

• Regulatory

• Legal

• Compliance-driven

This is where the combined model becomes critical.

Andersen provides:

• Global regulatory expertise

• Legal structuring

• Compliance frameworks

Stratence provides:

• Commercial transformation capability

• Pricing and GTN control

• AI-powered decision systems

Together:

Compliance is not just ensured

It is transformed into competitive advantage

7. What Leading Pharma Organizations Are Doing Now

Leading players are not waiting.

They are already:

• Mapping global reference exposure across portfolios

• Redesigning gross-to-net structures across key markets

• Embedding simulation capabilities into launch decisions

• Aligning Market Access, Pricing, and Commercial governance

They are shifting from:

Reactive pricing adjustments

to

Proactive commercial system control

Conclusion: The MFN Paradox

MFN creates a paradox.

The more global the pricing system becomes... the more local decisions destroy value.

The only way to resolve this paradox is:

• To treat pricing as a system

• To control decisions end-to-end

• To embed intelligence into execution

Organizations that do this will:

• Protect margins

• Accelerate decision-making

• Gain competitive advantage

Those that do not:

Will see their global asset value eroded... by decisions they did not even realize they were making.

Final Thought

MFN is not the end of pricing strategy.

It is the beginning of commercial system design.

And that is exactly where Stratence operates.